+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID07609914

Safety and Tolerability of Redosing Rimegepant for Acute Migraine Treatment in Adults

Led by Pfizer · Updated on 2026-10-14

400

Participants Needed

24

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and tolerability of taking an additional dose of the medicine rimegepant for adults with migraine who may not get full pain relief from the first dose. The study focuses on people aged 18 or older with a history of migraine and examines whether a second dose within 24 hours can help manage migraine attacks better. This research is a Phase 4, open-label trial sponsored by Pfizer, aiming to understand the effects of redosing rimegepant for acute migraine treatment. Participants will take rimegepant 75 mg orally disintegrating tablet ODT to treat moderate or severe migraine attacks. If they are not pain-free about 2 hours after the first dose or experience headache relapse after initial relief, they may take a second dose within 24 hours. This redosing can occur up to 10 times per month over a 24-week open-label treatment phase. During the study, participants will be monitored for treatment-emergent adverse events and liver function test changes related to redosing frequency. Satisfaction with headache pain reduction and impact on daily activities will also be assessed. The study involves regular evaluation over up to 6 months to measure tolerability, safety, and participant-reported outcomes while using rimegepant for acute migraine attacks.

CONDITIONS

Brief Title

A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

Research Team

P

Pfizer CT.gov Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here